hPL*-GdDTPA

**hPL*-GdDTPA** is an investigational contrast agent designed for enhanced imaging in magnetic resonance imaging (MRI), integrating human placental lactogen (hPL*) with gadolinium-diethylenetriaminepentaacetic acid (GdDTPA). GdDTPA is a widely used paramagnetic MRI contrast agent that shortens relaxation times (T1 and T2) of surrounding water protons, increasing imaging signal intensity in tissues where the agent accumulates[1]. While the parent GdDTPA is well characterized for MRI contrast, the "hPL*" modification suggests targeting, most likely towards tissues expressing the hPL receptor, potentially aiding tumor-specific imaging or theranostic applications. The complex is likely excreted renally; the biological properties of hPL* in drug targeting or imaging still require thorough preclinical validation. No commercial or approved products containing hPL*-GdDTPA are identified in public listings; the name suggests either a research reagent or early-stage developmental compound.

Brand names

hPL*-GdDTPA

Other names

hPL*-GdDTPA